Inhibitors of pathogen-derived CdnP or host-derived ENPP1, therefore, offer a means to exploit the cGAS-STING pathway toward the management of bacterial infections and solid tumor immunotherapy while minimizing adverse effects of systemic STING activation (32, 34). The gene discussed is STING1; the disease is bacterial infectious disease.